Human Germline Genome Editing

American Journal of Human Genetics

Volumn 101, Issue 2, 2017, Pages 167-176

  Ormond, Kelly E ^a   Mortlock, Douglas P ^b   Scholes, Derek T ^c   Bombard, Yvonne ^d   Brody, Lawrence C ^e   Faucett, W Andrew ^f,g   Garrison, Nanibaa’ A ^h,i   Hercher, Laura ^g,j   Isasi, Rosario ^k   Middleton, Anna ^l,m   Musunuru, Kiran ⁿ   Shriner, Daniel ^e,o   Virani, Alice ^p,q   Young, Caroline E ^c  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c American Society of Human Genetics   (United States)

^d ST MICHAEL'S HOSPITAL   (Canada)

^e NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^f GEISINGER HEALTH SYSTEM   (United States)

^g National Society of Genetic Counselors   (United States)

^h SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

ⁱ UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^j SARAH LAWRENCE COLLEGE   (United States)

^k UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^l Society and Ethics Research   (United Kingdom)

^m Association of Genetic Nurses and Counsellors   (United States)

ⁿ UNIVERSITY OF PENNSYLVANIA   (United States)

^o International Genetic Epidemiology Society   (United States)

^p UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^q Canadian Association of Genetic Counsellors   (Canada)

more..

Author keywords

CRISPR; ethics; eugenics; gene editing; gene therapy; genetics policy; genome editing; germline; human genome; society

Indexed keywords

CLINICAL EFFECTIVENESS; CRISPR CAS SYSTEM; DONOR; GAMETE; GENE EDITING; GERM LINE; HUMAN; MEDICAL ETHICS; NONHUMAN; POLICY; PRECLINICAL STUDY; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SAFETY; SCIENTIFIC LITERATURE; SOMATIC GENE THERAPY; STREPTOCOCCUS PYOGENES; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEAT; ETHICS; GENETICS; HUMAN GENOME; LEGISLATION AND JURISPRUDENCE; PROCEDURES; SOCIAL CHANGE;

CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEATS; GENE EDITING; GENOME, HUMAN; HUMANS; SOCIAL CHANGE;

EID: 85029548387     PISSN: 00029297     EISSN: 15376605     Source Type: Journal    
DOI: 10.1016/j.ajhg.2017.06.012     Document Type: Review

References (61)

1. Hsu, P.D., Lander, E.S., Zhang, F., Development and applications of CRISPR-Cas9 for genome engineering. Cell 157 (2014), 1262–1278.
2. Gupta, R.M., Musunuru, K., Expanding the genetic editing tool kit: ZFNs, TALENs, and CRISPR-Cas9. J. Clin. Invest. 124 (2014), 4154–4161.
3. Komor, A.C., Badran, A.H., Liu, D.R., CRISPR-based technologies for the manipulation of eukaryotic genomes. Cell 168 (2017), 20–36.
4. Wirth, T., Parker, N., Ylä-Herttuala, S., History of gene therapy. Gene 525 (2013), 162–169.
5. Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J.A., Charpentier, E., A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337 (2012), 816–821.
6. Mali, P., Yang, L., Esvelt, K.M., Aach, J., Guell, M., DiCarlo, J.E., Norville, J.E., Church, G.M., RNA-guided human genome engineering via Cas9. Science 339 (2013), 823–826.
7. Cong, L., Ran, F.A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P.D., Wu, X., Jiang, W., Marraffini, L.A., Zhang, F., Multiplex genome engineering using CRISPR/Cas systems. Science 339 (2013), 819–823.
8. Jinek, M., East, A., Cheng, A., Lin, S., Ma, E., Doudna, J., RNA-programmed genome editing in human cells. eLife, 2, 2013, e00471.
9. Cho, S.W., Kim, S., Kim, J.M., Kim, J.S., Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. Nat. Biotechnol. 31 (2013), 230–232.
10. Ding, Q., Regan, S.N., Xia, Y., Oostrom, L.A., Cowan, C.A., Musunuru, K., Enhanced efficiency of human pluripotent stem cell genome editing through replacing TALENs with CRISPRs. Cell Stem Cell 12 (2013), 393–394.
11. Wang, H., Yang, H., Shivalila, C.S., Dawlaty, M.M., Cheng, A.W., Zhang, F., Jaenisch, R., One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. Cell 153 (2013), 910–918.
12. Ding, Q., Strong, A., Patel, K.M., Ng, S.L., Gosis, B.S., Regan, S.N., Cowan, C.A., Rader, D.J., Musunuru, K., Permanent alteration of PCSK9 with in vivo CRISPR-Cas9 genome editing. Circ. Res. 115 (2014), 488–492.
13. Li, D., Qiu, Z., Shao, Y., Chen, Y., Guan, Y., Liu, M., Li, Y., Gao, N., Wang, L., Lu, X., et al. Heritable gene targeting in the mouse and rat using a CRISPR-Cas system. Nat. Biotechnol. 31 (2013), 681–683.
14. Niu, Y., Shen, B., Cui, Y., Chen, Y., Wang, J., Wang, L., Kang, Y., Zhao, X., Si, W., Li, W., et al. Generation of gene-modified cynomolgus monkey via Cas9/RNA-mediated gene targeting in one-cell embryos. Cell 156 (2014), 836–843.
15. Yen, S.T., Zhang, M., Deng, J.M., Usman, S.J., Smith, C.N., Parker-Thornburg, J., Swinton, P.G., Martin, J.F., Behringer, R.R., Somatic mosaicism and allele complexity induced by CRISPR/Cas9 RNA injections in mouse zygotes. Dev. Biol. 393 (2014), 3–9.
16. Singh, P., Schimenti, J.C., Bolcun-Filas, E., A mouse geneticist's practical guide to CRISPR applications. Genetics 199 (2015), 1–15.
17. Liang, P., Xu, Y., Zhang, X., Ding, C., Huang, R., Zhang, Z., Lv, J., Xie, X., Chen, Y., Li, Y., et al. CRISPR/Cas9-mediated gene editing in human tripronuclear zygotes. Protein Cell 6 (2015), 363–372.
18. Fu, Y., Foden, J.A., Khayter, C., Maeder, M.L., Reyon, D., Joung, J.K., Sander, J.D., High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nat. Biotechnol. 31 (2013), 822–826.
19. Hsu, P.D., Scott, D.A., Weinstein, J.A., Ran, F.A., Konermann, S., Agarwala, V., Li, Y., Fine, E.J., Wu, X., Shalem, O., et al. DNA targeting specificity of RNA-guided Cas9 nucleases. Nat. Biotechnol. 31 (2013), 827–832.
20. Mali, P., Aach, J., Stranges, P.B., Esvelt, K.M., Moosburner, M., Kosuri, S., Yang, L., Church, G.M., CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. Nat. Biotechnol. 31 (2013), 833–838.
21. Pattanayak, V., Lin, S., Guilinger, J.P., Ma, E., Doudna, J.A., Liu, D.R., High-throughput profiling of off-target DNA cleavage reveals RNA-programmed Cas9 nuclease specificity. Nat. Biotechnol. 31 (2013), 839–843.
22. Veres, A., Gosis, B.S., Ding, Q., Collins, R., Ragavendran, A., Brand, H., Erdin, S., Cowan, C.A., Talkowski, M.E., Musunuru, K., Low incidence of off-target mutations in individual CRISPR-Cas9 and TALEN targeted human stem cell clones detected by whole-genome sequencing. Cell Stem Cell 15 (2014), 27–30.
23. Smith, C., Gore, A., Yan, W., Abalde-Atristain, L., Li, Z., He, C., Wang, Y., Brodsky, R.A., Zhang, K., Cheng, L., Ye, Z., Whole-genome sequencing analysis reveals high specificity of CRISPR/Cas9 and TALEN-based genome editing in human iPSCs. Cell Stem Cell 15 (2014), 12–13.
24. Slaymaker, I.M., Gao, L., Zetsche, B., Scott, D.A., Yan, W.X., Zhang, F., Rationally engineered Cas9 nucleases with improved specificity. Science 351 (2016), 84–88.
25. Kleinstiver, B.P., Pattanayak, V., Prew, M.S., Tsai, S.Q., Nguyen, N.T., Zheng, Z., Joung, J.K., High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects. Nature 529 (2016), 490–495.
26. Araki, M., Ishii, T., International regulatory landscape and integration of corrective genome editing into in vitro fertilization. Reprod. Biol. Endocrinol., 12, 2014, 108.
27. Ledford, H., Where in the world could the first CRISPR baby be born?. Nature 526 (2015), 310–311.
28. Isasi, R., Kleiderman, E., Knoppers, B.M., GENETIC TECHNOLOGY REGULATION. Editing policy to fit the genome?. Science 351 (2016), 337–339.
29. Drazen, J.M., Embryonic stem-cell research–the case for federal funding. N. Engl. J. Med. 351 (2004), 1789–1790.
30. Office of the Press Secretary (2001). President Discusses Stem Cell Research. The White House, https://georgewbush-whitehouse.archives.gov/news/releases/2001/08/20010809-2.html.
31. National Institutes of Health, Office of Extramural Research (2016). 4 Public Policy Requirements, Objectives, and Other Appropriation Mandates. NIH, https://grants.nih.gov/grants/policy/nihgps/HTML5/section_4/4_public_policy_requirements__objectives_and_other_appropriation_mandates.htm.
32. Canadian Pediatric Society. Treatment decisions regarding infants, children and adolescents. Paediatr. Child Health 9 (2004), 99–114.
33. Diekema, D., Mercurio, M., Adam, B., Clinical Ethics in Pediatrics: A case based textbook. 2011, Cambridge University Press.
34. Botkin, J.R., The legal concept of wrongful life. JAMA 259 (1988), 1541–1545.
35. Check Hayden, E., Should you edit your children's genes?. Nature 530 (2016), 402–405.
36. Botkin, J.R., Belmont, J.W., Berg, J.S., Berkman, B.E., Bombard, Y., Holm, I.A., Levy, H.P., Ormond, K.E., Saal, H.M., Spinner, N.B., et al. Points to consider: ethical, legal, and psychosocial implications of genetic testing in children and adolescents. Am. J. Hum. Genet. 97 (2015), 6–21.
37. Committee on Bioethics Committee on Genetics, American College of Medical Genetics and Genomics Social, Ethical, and Legal Issues Committee. Ethical and policy issues in genetic testing and screening of children. Pediatrics 131 (2013), 620–622.
38. Egan, J.F., Smith, K., Timms, D., Bolnick, J.M., Campbell, W.A., Benn, P.A., Demographic differences in Down syndrome livebirths in the US from 1989 to 2006. Prenat. Diagn. 31 (2011), 389–394.
39. Savulescu, J., Procreative beneficence: why we should select the best children. Bioethics 15 (2001), 413–426.
40. Jacobs, B.M., Is there a moral obligation to select healthy children?. J. Med. Ethics 41 (2015), 696–700.
41. Funk, C., Kennedy, B., and Sciupac, E.P. (2016). U.S. public opinion on the future use of gene editing. Pew Research Center, http://www.pewinternet.org/2016/07/26/u-s-public-opinion-on-the-future-use-of-gene-editing/#.
42. Cho, M.K., Magnus, D., Caplan, A.L., McGee, D., Policy forum: genetics. Ethical considerations in synthesizing a minimal genome. Science 286 (1999), 2087–2090.
43. Hawkins, A.K., Hayden, M.R., A grand challenge: providing benefits of clinical genetics to those in need. Genet. Med. 13 (2011), 197–200.
44. Smith, C.E., Fullerton, S.M., Dookeran, K.A., Hampel, H., Tin, A., Maruthur, N.M., Schisler, J.C., Henderson, J.A., Tucker, K.L., Ordovás, J.M., Using Genetic Technologies To Reduce, Rather Than Widen, Health Disparities. Health Aff. (Millwood) 35 (2016), 1367–1373.
45. Rolland, J.S., Walsh, F., Facilitating family resilience with childhood illness and disability. Curr. Opin. Pediatr. 18 (2006), 527–538.
46. Bombard, Y., Bach, P.B., Offit, K., Translating genomics in cancer care. J. Natl. Compr. Canc. Netw. 11 (2013), 1343–1353.
47. Teutsch, S.M., Bradley, L.A., Palomaki, G.E., Haddow, J.E., Piper, M., Calonge, N., Dotson, W.D., Douglas, M.P., Berg, A.O., EGAPP Working Group. The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP Working Group. Genet. Med. 11 (2009), 3–14.
48. Bombard, Y., Abelson, J., Simeonov, D., Gauvin, F.P., Eliciting ethical and social values in health technology assessment: A participatory approach. Soc. Sci. Med. 73 (2011), 135–144.
49. Lehoux, P., Williams-Jones, B., Mapping the integration of social and ethical issues in health technology assessment. Int. J. Technol. Assess. Health Care 23 (2007), 9–16.
50. Davies, C., Wetherell, M., Barnett, E., Seymour-Smith, S., Opening the box. 2005, Evaluating the Citizens Council of NICE.
51. The Hinxton Group (2015). Statement on Genome Editing Technologies and Human Germline Genetic Modification. The Hinxton Group, http://www.hinxtongroup.org/Hinxton2015_Statement.pdf.
52. National Academies of Sciences, Engineering, and Medicine. (2015). On human gene editing: International summit statement. Eureka Alert, https://www.eurekalert.org/pub_releases/2015-12/naos-ohg120315.php.
53. National Academy of Sciences, National Academy of Medicine. Human Genome Editing: Science, Ethics, and Governance. 2017, National Academies Press.
54. Friedmann, T., Jonlin, E.C., King, N.M.P., Torbett, B.E., Wivel, N.A., Kaneda, Y., Sadelain, M., ASGCT and JSGT Joint Position Statement on Human Genomic Editing. Mol. Ther., 23, 2015, 1282.
55. International Society for Stem Cell Research (2015). The ISSCR Statement on Human Germline Genome Modification. ISSCR, http://www.isscr.org/home/about-us/news-press-releases/2015/2015/03/19/statement-on-human-germline-genome-modification.
56. Baltimore, D., Berg, P., Botchan, M., Carroll, D., Charo, R.A., Church, G., Corn, J.E., Daley, G.Q., Doudna, J.A., Fenner, M., et al. Biotechnology. A prudent path forward for genomic engineering and germline gene modification. Science 348 (2015), 36–38.
57. European Group on Ethics in Science and New Technologies (2016). Statement on Gene Editing. EGE, https://ec.europa.eu/research/ege/pdf/gene_editing_ege_statement.pdf#view=fit&pagemode=none.
58. Lanphier, E., Urnov, F., Haecker, S.E., Werner, M., Smolenski, J., Don't edit the human germ line. Nature 519 (2015), 410–411.
59. ACMG Board of Directors. Genome editing in clinical genetics: points to consider—a statement of the American College of Medical Genetics and Genomics. Genet. Med., 2017 Published online January 26, 2017.
60. Collins, F.S. (2015). Statement on NIH funding of research using gene-editing technologies in human embryos. NIH, https://www.nih.gov/about-nih/who-we-are/nih-director/statements/statement-nih-funding-research-using-gene-editing-technologies-human-embryos.
61. Human Fertilisation and Embryology Authority (2016). HFEA approval for new “gene editing” techniques. The Francis Crick Institute, https://www.crick.ac.uk/news/science-news/2016/02/01/hfea-decision/.